| [1] |
|
| [2] |
杨金秋, 赵文霞, 周铖, 等. 非酒精性脂肪性肝病发生进展期肝纤维化的危险因素及列线图预测模型构建[J]. 临床肝胆病杂志, 2024, 40(8): 1579-1584. DOI: 12449/JCH240812.
|
| [3] |
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
|
| [4] |
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
|
| [5] |
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036.
|
| [6] |
Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864. DOI: 10.1002/hep.31150.
|
| [7] |
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. DOI: 10.1038/s41575-020-00381-6.
|
| [8] |
Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab, 2021, 50: 101122. DOI: 10.1016/j.molmet.2020.101122.
|
| [9] |
Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes[J]. Clin Mol Hepatol, 2023, 29(suppl): S5-S16. DOI: 10.3350/cmh.2022.0424.
|
| [10] |
Hu N, Yan G, Tang M, et al. CT-based methods for assessment of metabolic dysfunction associated with fatty liver disease[J]. Eur Radiol Exp, 2023, 7(1): 72. DOI: 10.1186/s41747-023-00387-0.
|
| [11] |
Starekova J, Hernando D, Pickhardt PJ, et al. Quantification of liver fat content with CT and MRI: state of the art[J]. Radiology, 2021, 301(2): 250-262. DOI: 10.1148/radiol.2021204288.
|
| [12] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
|
| [13] |
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6): 1723-1730. DOI: 10.1002/hep.28123.
|
| [14] |
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study[J]. Hepatology, 2016, 63(3): 827-838. DOI: 10.1002/hep.28368.
|
| [15] |
Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases[J]. Aliment Pharmacol Ther, 2018, 48(7): 696-703. DOI: 10.1111/apt.14937.
|
| [16] |
Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review[J]. World J Hepatol, 2019, 11(1): 1-18. DOI: 10.4254/wjh.v11.i1.1.
|
| [17] |
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review[J]. JAMA, 2020, 323(12): 1175-1183. DOI: 10.1001/jama.2020.2298.
|
| [18] |
Parola M, Pinzani M. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies[J]. Mol Aspects Med, 2024, 95: 101231. DOI: 10.1016/j.mam.2023.101231.
|
| [19] |
Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1. 2 million men[J]. Gut, 2018, 67(8): 1536-1542. DOI: 10.1136/gutjnl-2016-313622.
|
| [20] |
Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 907-916. DOI: 10.1002/hep.30858.
|
| [21] |
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis[J]. PLoS Med, 2014, 11(4): e1001624. DOI: 10.1371/journal.pmed.1001624.
|
| [22] |
Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol, 2023, 8(7): 660-670. DOI: 10.1016/S2468-1253(23)00066-3.
|
| [23] |
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109. DOI: 10.1148/radiol.14140690.
|
| [24] |
Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 401-421. DOI: 10.1002/hep.29487.
|
| [25] |
Kobayashi S, Matsui O, Gabata T, et al. Hemodynamics of small sclerosing hepatocellular carcinoma without fibrous capsule: evaluation with single-level dynamic CT during hepatic arteriography[J]. Abdom Imaging, 2008, 33(4): 425-427. DOI: 10.1007/s00261-007-9288-z.
|
| [26] |
Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH[J]. Cells, 2020, 9(4): 1005. DOI: 10.3390/cells9041005.
|
| [27] |
Zhou JH, Cai JJ, She ZG, et al. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice[J]. World J Gastroenterol, 2019, 25(11): 1307-1326. DOI: 10.3748/wjg.v25.i11.1307.
|
| [28] |
Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD[J]. Clin Gastroenterol Hepatol, 2023, 21(8): 2026-2039. DOI: 10.1016/j.cgh.2023.03.042.
|
| [29] |
Foerster F, Gairing SJ, Müller L, et al. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options[J]. J Hepatol, 2022, 76(2): 446-457. DOI: 10.1016/j.jhep.2021.09.007.
|
| [30] |
Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers[J]. Cancer Metastasis Rev, 2023, 42(3): 629-652. DOI: 10.1007/s10555-023-10084-4.
|
| [31] |
Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 293-313. DOI: 10.1038/s41575-020-00395-0.
|